Secondary hyperparathyroidism is a condition where your parathyroid glands produce too much parathyroid hormone (PTH) in response to another problem in your body, most commonly chronic kidney disease. Unlike primary hyperparathyroidism, where a gland itself is faulty, secondary hyperparathyroidism is a reaction: something else drives calcium too low or phosphorus too high, and your parathyroid glands overwork to compensate. Prevalence estimates range from 20% to 80% of people with chronic kidney disease, depending on the stage.
How It Develops
Your four parathyroid glands sit behind the thyroid in your neck. Their job is straightforward: monitor blood calcium levels and release PTH when calcium drops too low. PTH then pulls calcium from bone, increases calcium absorption in the gut, and tells the kidneys to hold onto calcium rather than excrete it. In a healthy system, calcium rises back to normal and the glands dial PTH back down.
In secondary hyperparathyroidism, something keeps calcium chronically low or phosphorus chronically high, so the glands never get the signal to stop. The most common trigger is chronic kidney disease. As kidney function declines, two things happen simultaneously. First, the kidneys lose the ability to convert vitamin D into its active form, which means your gut absorbs less calcium from food. Second, the kidneys can no longer excrete phosphorus efficiently, so phosphorus builds up in the blood. High phosphorus directly stimulates PTH production and also binds to calcium, lowering the amount of free calcium available.
This combination of low calcium, high phosphorus, and low active vitamin D creates a persistent drive for the parathyroid glands to keep producing PTH. Within hours to days, ongoing low calcium and high phosphorus ramp up the genes that make PTH. Over months and years, the glands physically enlarge, a process called hyperplasia. Once enlarged, they become harder to control with medication alone.
Chronic Kidney Disease Is the Primary Driver
While other conditions like severe vitamin D deficiency, gut malabsorption disorders, and obesity can trigger secondary hyperparathyroidism, chronic kidney disease accounts for the vast majority of cases. The incidence climbs steeply as kidney function worsens: roughly 57 new cases per 1,000 person-years in stage 3 CKD, jumping to 230 per 1,000 person-years by stage 5. By the time someone reaches dialysis, the condition is nearly universal.
A signaling molecule called fibroblast growth factor 23 (FGF23) also plays a role. Produced by bone cells, FGF23 rises early in kidney disease as the body tries to force the kidneys to excrete more phosphorus. It succeeds for a while, but at the cost of further suppressing active vitamin D production, which feeds right back into the cycle driving PTH higher.
How It Differs From Primary Hyperparathyroidism
The distinction matters because the causes, lab results, and treatments differ significantly. In primary hyperparathyroidism, one or more parathyroid glands develop a benign tumor or grow abnormally on their own, pumping out PTH regardless of calcium levels. The hallmark is high blood calcium (often averaging around 12 mg/dL) paired with inappropriately elevated PTH. Phosphorus tends to run low because excess PTH forces the kidneys to dump it.
Secondary hyperparathyroidism looks almost like a mirror image. Blood calcium is typically low or low-normal, phosphorus is high (especially in kidney disease), and PTH is elevated as a compensatory response. If you correct the underlying problem, such as restoring vitamin D levels or improving kidney function, the parathyroid glands can return to normal. In primary hyperparathyroidism, the glands won’t self-correct.
Symptoms
Early secondary hyperparathyroidism often produces no obvious symptoms. Many people learn about it from routine blood work showing elevated PTH. As the condition progresses, symptoms can include bone and joint pain, generalized weakness, fatigue, and persistent itchy skin (pruritus). These symptoms are nonspecific, meaning they overlap with many other conditions and with the effects of kidney disease itself, which makes them easy to overlook.
Over time, chronically elevated PTH pulls calcium from bones, weakening them. This can lead to fractures, particularly in the spine, hips, and wrists. In severe cases, bones develop a characteristic appearance on X-rays, with bands of increased and decreased density in the spine.
Cardiovascular Risks
The most serious long-term consequence of uncontrolled secondary hyperparathyroidism is cardiovascular disease. Cardiovascular events account for nearly 50% of deaths in people on dialysis, and vascular calcification is a strong predictor of that mortality. When calcium and phosphorus levels stay elevated together, calcium-phosphorus crystals deposit in artery walls, heart valves, and soft tissues. This stiffens arteries and accelerates heart disease.
The calcium-phosphorus product (calcium level multiplied by phosphorus level) has been identified as the most reliable risk factor for this type of calcification. One study found that ectopic calcification was present in 60% of kidney disease patients with secondary hyperparathyroidism. This is why controlling phosphorus and calcium levels is not just about bones; it is directly about survival.
How It Is Diagnosed
Diagnosis relies on blood tests. The current KDIGO (Kidney Disease: Improving Global Outcomes) guidelines, the most widely used clinical framework, set target ranges for people with end-stage kidney disease: calcium between 8.4 and 10.2 mg/dL, phosphorus between 2.5 and 4.6 mg/dL, and PTH between two to nine times the upper limit of normal (roughly 130 to 600 pg/mL). PTH levels above this range, combined with the expected calcium and phosphorus abnormalities, confirm the diagnosis.
Your doctor will also check vitamin D levels, as deficiency is both a cause and an aggravating factor. Imaging is not typically needed for diagnosis but may be used to assess bone density or look for calcification in blood vessels.
Treatment: Medications
Treatment targets the underlying imbalances rather than the parathyroid glands directly. The two main classes of medication work through different mechanisms and have different trade-offs.
Active vitamin D compounds (calcitriol and paricalcitol) replace the active vitamin D that failing kidneys can no longer produce. They improve calcium absorption from the gut, which helps suppress PTH. The downside is that they raise blood calcium, which can be counterproductive if calcium is already creeping upward or if the calcium-phosphorus product is high.
Calcimimetics work differently. They make the parathyroid glands more sensitive to whatever calcium is already in the blood, essentially tricking the glands into thinking calcium is higher than it is. This lowers PTH without raising calcium. In fact, both cinacalcet (taken as a pill) and etelcalcetide (given intravenously during dialysis) tend to lower calcium levels. They also reduce the calcium-phosphorus product more effectively than vitamin D compounds. The trade-off is gastrointestinal side effects: nausea, vomiting, and diarrhea are significantly more common with calcimimetics than with vitamin D therapy.
Many patients end up on a combination of both approaches, with doses adjusted based on regular lab monitoring.
The Role of Diet
Dietary phosphorus restriction is a cornerstone of managing secondary hyperparathyroidism in kidney disease. The goal is to keep serum phosphorus within the normal reference range. Foods particularly high in phosphorus per serving include hard cheeses (464 to 602 mg per 100 g), sesame seeds (616 mg), walnuts (510 mg), pistachio nuts (500 mg), almonds (440 mg), canned sardines (489 mg), and canned salmon (326 mg). Processed foods also tend to contain phosphorus-based additives that are absorbed more readily than naturally occurring phosphorus.
Calcium intake for people with kidney disease is generally recommended at 800 to 1,000 mg per day, slightly lower than the 1,000 to 1,200 mg recommended for the general population, because excess calcium in the setting of high phosphorus accelerates vascular calcification. Vitamin D intake of 400 to 800 IU per day is also suggested, though many patients need prescription-strength active vitamin D beyond what diet alone provides. When diet is not enough to control phosphorus, phosphate binders taken with meals can help prevent phosphorus absorption from food.
When Surgery Becomes Necessary
Parathyroidectomy, the surgical removal of some or all parathyroid tissue, is reserved for people whose condition does not respond to medication. The typical threshold is a PTH level persistently above 800 pg/mL along with high calcium or high phosphorus that cannot be controlled with drug therapy. Before surgery is considered, treatable factors like vitamin D deficiency and inadequate phosphorus management should be optimized first.
Symptoms like bone pain, itching, and weakness can support the decision to operate, but they are not sufficient on their own since they have many possible causes. Calciphylaxis, a rare and painful condition involving skin ulcers and tissue death from calcification of small blood vessels, has traditionally been linked to longstanding hyperparathyroidism. However, more recent data suggests other factors like blood-thinning medication may play a larger role, and studies have not shown a clear mortality benefit from surgery for calciphylaxis specifically.
For patients who undergo parathyroidectomy, recurrence is possible. Some surgeons use the same criteria for repeat surgery: PTH above 800 pg/mL with uncontrolled calcium or phosphorus despite medical therapy.